Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Swaminathan Padmanabhan, MD, Roger Strair, MD, Mark Kirschbaum, MD, Peter Maslak, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Susan O'Brien, Felipe Samaniego, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Lyubomir Vassilev, PhD, Gwen Nichols, MD

Blood (2010) 116 (21): 657.

https://doi.org/10.1182/blood.V116.21.657.657

Published: 2010

Journal Articles

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Kristen M O'Dwyer, M.D., David Shum, M.S., Mark Heaney, MD, PhD, Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Mark G. Frattini, MD, PhD

Blood (2009) 114 (22): 2657.

https://doi.org/10.1182/blood.V114.22.2657.2657

Published: 2009

Journal Articles

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O'Dwyer, M.D., Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Mark Heaney, MD, PhD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.

Blood (2009) 114 (22): 3771.

https://doi.org/10.1182/blood.V114.22.3771.3771

Published: 2009

Journal Articles

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O’Dwyer, M.D., Renier J. Brentjens, MD, PhD, Ray Yeh, Ph.D., Peter Maslak, MD, Mark Lawrence Heaney, MD, PhD, Joseph Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.

Blood (2008) 112 (11): 2668.

https://doi.org/10.1182/blood.V112.11.2668.2668

Published: 2008

Journal Articles

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Mark G. Frattini, MD, PhD, Elmer Santos, MD, PhD, Mark Lawrence Heaney, MD, PhD, Peter Maslak, MD, Suresh C Jhanwar, PhD, Steven M Larson, MD, Elisa De Stanchina, PhD, Bayard Clarkson, MD, Renier J. Brentjens, MD, PhD

Blood (2008) 112 (11): 4875.

https://doi.org/10.1182/blood.V112.11.4875.4875

Published: 2008

Journal Articles

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Ping Zhou, MD, PhD, Adam M Boruchov, MD, James E. Hoffman, MD, Qianxing Mo, Adam Olshen, Evan Glasner, Ezio Bonvini, Scott Koenig, Ellen Drieghe, Martin Fleisher, PhD, Peter Maslak, MD, Hani Hassoun, MD, Adam D Cohen, MD, Heather Landau, MD, James W. Young, MD, Suresh C Jhanwar, PhD, Stephen D Nimer, MD, Raymond L Comenzo

Blood (2008) 112 (11): 842.

https://doi.org/10.1182/blood.V112.11.842.842

Published: 2008

Journal Articles

Validation of Flow Cytometric Measurements of NK Cytotoxicity Against Chromium Release Assay for Use in Clinical Monitoring of Immune Function.

Katherine Smith, BA, Glenn Heller, PhD, Peter Maslak, MD

Blood (2006) 108 (11): 5287.

https://doi.org/10.1182/blood.V108.11.5287.5287

Published: 2006

Journal Articles

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

Peter Maslak, MD, James Caravelli, MD, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 2834.

https://doi.org/10.1182/blood.V108.11.2834.2834

Published: 2006

Journal Articles

CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.

Adam Boruchov, MD, P. Zhou, MD, PhD, A. Olshen, PhD, C. Rankin, E. Bonvini, MD, S. Koenig, MD, PhD, M. Fleisher, PhD, R. Rose, S. McKenzie, Peter Maslak, MD, Suresh C. Jhanwar, PhD, James W. Young, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2006) 108 (11): 3489.

https://doi.org/10.1182/blood.V108.11.3489.3489

Published: 2006

Journal Articles

CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.

Rena J. May, PhD, Javier Pinilla, MD PhD, Tatyana Korontsvit, Victoriya Zakhaleva, Ronghua H. Zhang, Tao Dao, MD PhD, Peter Maslak, MD, David A. Scheinberg, MD PhD

Blood (2006) 108 (11): 3706.

https://doi.org/10.1182/blood.V108.11.3706.3706

Published: 2006

Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Mark L. Heaney, MD, PhD, Renier Brentjens, MD, PhD, Joseph Jurcic, MD, Emily Biederman, Alison N. Gencarelli, RN, Katherine S. Panageas, PhD, David A. Scheinberg, MD, PhD, Mark A. Weiss, MD

Blood (2005) 106 (11): 2127.

https://doi.org/10.1182/blood.V106.11.2127.2127

Published: 2005

Journal Articles

Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Joseph Jurcic, MD, David A. Scheinberg, MD, PhD, Alison N. Gencarelli, RN, Denise Horgan, Mark A. Weiss, MD

Blood (2004) 104 (11): 3484.

https://doi.org/10.1182/blood.V104.11.3484.3484

Published: 2004

NARROW

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo .

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Validation of Flow Cytometric Measurements of NK Cytotoxicity Against Chromium Release Assay for Use in Clinical Monitoring of Immune Function.

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.

CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only